| Date | Time | Source | Headline | Symbol | Company |
| 06/13/2006 | 8:12AM | PR Newswire (US) | Allos Therapeutics Files Shelf Registration Statement | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/07/2006 | 9:00AM | PR Newswire (US) | Allos Therapeutics to Present at the 2006 Needham & Company Biotechnology Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/05/2006 | 7:07PM | PR Newswire (US) | Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/05/2006 | 9:00AM | PR Newswire (US) | Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/25/2006 | 4:33PM | PR Newswire (US) | Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/09/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics Reports First Quarter 2006 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 04/04/2006 | 8:00AM | PR Newswire (US) | Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/10/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics Appoints Paul L. Berns as President and CEO | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/06/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics Reports 2005 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 03/01/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics to Present at the 2006 Cowen Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/14/2006 | 8:00AM | PR Newswire (US) | Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Mo | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 02/01/2006 | 8:00AM | PR Newswire (US) | Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/16/2006 | 7:22PM | PR Newswire (US) | Allos Therapeutics Announces CEO Succession Plans | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 01/03/2006 | 8:00AM | PR Newswire (US) | Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Ori | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/12/2005 | 8:02AM | PR Newswire (US) | Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating F | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 12/12/2005 | 8:00AM | PR Newswire (US) | PDX Shows Promising Activity in Patients With Resistant T-Cell Lymphomas | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/17/2005 | 8:02AM | PR Newswire (US) | Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/17/2005 | 8:01AM | PR Newswire (US) | Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/16/2005 | 8:00AM | PR Newswire (US) | Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/09/2005 | 8:02AM | PR Newswire (US) | Allos Therapeutics Reports Third Quarter 2005 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 11/08/2005 | 8:02AM | PR Newswire (US) | Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/21/2005 | 12:02PM | PR Newswire (US) | Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/13/2005 | 9:01AM | PR Newswire (US) | Allos Therapeutics to Present at the 2005 BIO Investor Forum | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 10/11/2005 | 6:06PM | PR Newswire (US) | Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 09/22/2005 | 9:00AM | PR Newswire (US) | Allos Therapeutics to Present at the UBS Global Life Sciences Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 09/07/2005 | 9:02AM | PR Newswire (US) | Allos Therapeutics to Present at the Bear Stearns Healthcare Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 09/01/2005 | 9:00AM | PR Newswire (US) | Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Recei | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/08/2005 | 9:01AM | PR Newswire (US) | Allos Therapeutics Reports Second Quarter 2005 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/16/2005 | 3:28PM | PR Newswire (US) | Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/19/2005 | 6:46PM | PR Newswire (US) | Allos Therapeutics Announces Stockholder Approval of Share Exchange | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |